Cervical Tissue Derived Organ Culture to Test Microbicides
宫颈组织衍生器官培养以测试杀菌剂
基本信息
- 批准号:7681868
- 负责人:
- 金额:$ 29.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-01 至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:Antiviral AgentsApplications GrantsBacteriaBiological AssayCell Culture SystemCell Culture TechniquesCellsCervicalCervix UteriClinical TrialsCollaborationsComplementDataDevelopmentDrug FormulationsEnvironmental Risk FactorEpitheliumEvaluationGenital systemHIVHIV-1HIV-1 vaccineHistocompatibilityHistologyIL8 geneImmuneIn VitroInfectionInflammationInflammatoryInflammatory Response PathwayInterleukin-6MeasuresMemoryModelingMonitorMonkeysMucous MembraneNeisseria gonorrhoeaeNucleosidesOrgan Culture TechniquesOutcomeOutcome StudyPeptidesPhysiologicalPrevotella melaninogenicaPrincipal InvestigatorPropertyReverse Transcriptase InhibitorsScreening procedureSeminal fluidSexually Transmitted DiseasesSystemTestingTimeTissuesTopical applicationToxic effectVaginaVaginal Ringanti-HIV microbicideantimicrobial peptidebasecell injurycytokinecytotoxiccytotoxicitycytotoxicity testgenital secretionin vitro Assayin vivoinhibitor/antagonistmicrobicidemicroorganismnon-nucleoside reverse transcriptase inhibitorspinacolyl methylphosphonic acidpreclinical evaluationpreventprogramsresponseretrocyclinsimian human immunodeficiency virustooltransmission processvaginal fluidvaginal microbicide
项目摘要
The in vitro cell culture system has been widely used as a primary screening tool for evaluating anti-HIV-1
activity of microbicides. However, there is clearly a need to develop a vaginal and cervical tissue based in
vitro system to test the cytotoxicity and antiviral activity in the context of the complete tissue matrix. We have
recently developed a cervical tissue-derived organ culture model which mimics in vivo conditions and has
been used to test microbicides for their ability to block HIV-1 transmission and measure inflammatory
cytokines in response to microbicides and sexually transmitted infection-related bacteria. Our hypothesis is
that a cervical tissue-based organ culture is an ideal system to test microbicides for toxicity in genital tissue
and for its ability to block transmission of HIV-1 with varying phenotypic properties across the cervical
epithelium in the presence of common environmental factors that are present in vagina, such as semen,
vaginal fluid, and STI-related microorganisms. Specific aims of the project are: 1) Evaluation of -nucleoside
reverse transcriptase inhibitor (NNRTI) 5-chloro-3-phenylsulfonylindole-2-carboxamide (CSIC) from Project 1
and the entry inhibitor antimicrobial peptide retrocyclin RC101 from Project 2 alone or in combination and
their formulations for their ability to block HIV-1 transmission across the mucosa in a cervical tissue-based
organ culture. 2) Assessment of cervical tissue inflammation and their changes in response to CSIC and
RC101 from Projects 1 and 2, respectively, using the organ culture model. The expression of
proinflammatory cytokines, such as 11-13, IL-6, IL-8 and TNF-a will be monitored by measuring their
messages in the tissues by the real time PCR and secretion in the culture supernatant using the Luminex
system; 3) Evaluation of anti-HIV activity of CSIC and RC101 under physiologically relevant conditions. CSIC
and RC101 alone or in combination and their formulations will be evaluated for their antiviral activities in the
presence of semen and vaginal fluid. In addition the organ culture model will be expanded to measure STIrelated
microorganisms, such as Neisseria gonorrhoeae and Prevotella melaninogenica by measuring
proinflammatory cytokine response. Microbicides will then be evaluated for their antiviral activity in the
aresence of the proinflammatory cytokines induced by these microorganisms.The proposed studies in this
Droject will complement various other projects in this U19 grant application by providing a valuable in vitro
cervical tissue-based assay which will bridge between the microbicide development (Projects 1 and 2),
monkey model (Project 4) and Formulation Core (Core B).
体外细胞培养系统已被广泛用作评估抗hiv -1的主要筛选工具
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Phalguni GUPTA其他文献
Phalguni GUPTA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Phalguni GUPTA', 18)}}的其他基金
Pitt HIV-TB research and training program in India
皮特在印度的艾滋病毒结核病研究和培训项目
- 批准号:
9545359 - 财政年份:2015
- 资助金额:
$ 29.26万 - 项目类别:
Mucosal Chemokines and Inflammation in SIV Transmission and Pathogenesis
SIV 传播和发病机制中的粘膜趋化因子和炎症
- 批准号:
8724017 - 财政年份:2013
- 资助金额:
$ 29.26万 - 项目类别:
RT Inhibitor CSIC and Entry Inhibitor Retrocyclin RC101 as Microbicides
RT 抑制剂 CSIC 和进入抑制剂 Retrocyclin RC101 作为杀微生物剂
- 批准号:
7920894 - 财政年份:2009
- 资助金额:
$ 29.26万 - 项目类别:
RT Inhibitor CSIC and Entry Inhibitor Retrocyclin RC101 as Microbicides
RT 抑制剂 CSIC 和进入抑制剂 Retrocyclin RC101 作为杀微生物剂
- 批准号:
7662754 - 财政年份:2009
- 资助金额:
$ 29.26万 - 项目类别:
A Novel Approach to Identify HIV Suppression Factor from CD8 Cells
从 CD8 细胞中鉴定 HIV 抑制因子的新方法
- 批准号:
7871341 - 财政年份:2009
- 资助金额:
$ 29.26万 - 项目类别:
RT Inhibitor CSIC and Entry Inhibitor Retrocyclin RC101 as Microbicides
RT 抑制剂 CSIC 和进入抑制剂 Retrocyclin RC101 作为杀微生物剂
- 批准号:
8135248 - 财政年份:2009
- 资助金额:
$ 29.26万 - 项目类别:
A Novel Approach to Identify HIV Suppression Factor from CD8 Cells
从 CD8 细胞中鉴定 HIV 抑制因子的新方法
- 批准号:
7755150 - 财政年份:2009
- 资助金额:
$ 29.26万 - 项目类别:
RT Inhibitor CSIC and Entry Inhibitor Retrocyclin RC101 as Microbicides
RT 抑制剂 CSIC 和进入抑制剂 Retrocyclin RC101 作为杀微生物剂
- 批准号:
8317579 - 财政年份:2009
- 资助金额:
$ 29.26万 - 项目类别:














{{item.name}}会员




